{"doi":"10.3390/ijms17122142","title":"Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis","abstract":"<jats:p>Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In previous years, many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e., RNA, DNA, protein and epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their study, paying specific attention to those able to assess heterogeneity at the single cell level.</jats:p>","journal":"International Journal of Molecular Sciences","year":2016,"id":594404,"datarank":0.7924805593106984,"base_score":5.2832037287379885,"endowment":5.2832037287379885,"self_citation_contribution":0.7924805593106984,"citation_network_contribution":0.0,"self_endowment_contribution":0.7924805593106984,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":196,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1521587,"name":"Benjamin Ory","orcid":null,"position":1,"is_corresponding":false},{"id":1521588,"name":"Francois Lamoureux","orcid":null,"position":2,"is_corresponding":false},{"id":1521589,"name":"Marie-Francoise Heymann","orcid":null,"position":3,"is_corresponding":false},{"id":1005662,"name":"Dominique Heymann","orcid":"0000-0001-7777-0669","position":4,"is_corresponding":false},{"id":1521586,"name":"Marta Tellez-Gabriel","orcid":"0000-0002-0895-2677","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis","abstract":"<jats:p>Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In previous years, many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e., RNA, DNA, protein and epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their study, paying specific attention to those able to assess heterogeneity at the single cell level.</jats:p>","is_dataset_classified":null,"base_score":5.2832037287379885,"endowment":5.2832037287379885,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"27999407","pmcid":"PMC5187942","openalex_id":"https://openalex.org/W2564119304","authors":[],"funders":[{"funder_name":"EU FP7","grant_id":"FP7/2007-2013","title":null},{"funder_name":"Bone Cancer Research Trust","grant_id":"144681","title":null},{"funder_name":"European Commission","grant_id":"264817","title":"European Training Network on Cancer-Induced Bone Diseases"}],"total_grants":3,"fwci":5.4262,"citation_percentile":0.96755389,"influential_citations":0,"citation_trend":[{"year":2017,"count":12},{"year":2018,"count":18},{"year":2019,"count":16},{"year":2020,"count":21},{"year":2021,"count":24},{"year":2022,"count":21},{"year":2023,"count":19},{"year":2024,"count":35},{"year":2025,"count":21},{"year":2026,"count":9}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1422-0067/17/12/2142/pdf?version=1482232075","host_type":"journal"},{"url":"https://www.mdpi.com/1422-0067/17/12/2142/pdf?version=1482232075","host_type":"publisher"},{"url":"https://www.mdpi.com/1422-0067/17/12/2142/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/ijms17122142","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/27999407","host_type":"repository"},{"url":"https://inserm.hal.science/inserm-01466086","host_type":"repository"},{"url":"https://doaj.org/article/e0e85b9fdec446a292b48c15449f6280","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/ijms17122142","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5187942","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC5187942","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC5187942?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.3390/ijms17122142","host_type":""},{"url":"https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6883","host_type":""},{"url":"https://inserm.hal.science/inserm-01466086v1/document","host_type":""},{"url":"https://inserm.hal.science/inserm-01466086v1","host_type":""},{"url":"https://eprints.whiterose.ac.uk/id/eprint/109440/","host_type":""},{"url":"https://doi.org/https://doi.org/10.3390/ijms17122142","host_type":""}],"fields_of_study":["Cancer Genomics and Diagnostics","Cancer Cells and Metastasis","Single-cell and spatial transcriptomics","0301 basic medicine","0303 health sciences","03 medical and health sciences"],"mesh_terms":["Humans","Neoplastic Cells, Circulating","Neoplasm Metastasis","Neoplasms","Phenotype","Genetic Heterogeneity","Single-Cell Analysis"],"keywords":["Tumour heterogeneity","Genetic heterogeneity","Epigenetics","Biology","Phenotype","Tumor heterogeneity","Disease","Cancer","Computational biology","Gene","Bioinformatics","Cancer research","Pathology","Genetics","Medicine","Heterogeneity","Single cells","Circulating Tumour Cells","[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism","[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics","[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system","610","[SDV.CAN]Life Sciences [q-bio]/Cancer","Review","[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism","Neoplastic Cells, Circulating","[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics","[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system","[SDV.CAN] Life Sciences [q-bio]/Cancer","Neoplasms","Humans","Neoplasm Metastasis","Single-Cell Analysis"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":16,"sdg_label":"16. Peace & justice"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T14:31:26.295094Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}